From Pulse 2.0 · Amit Chowdhry · · 1m
Estuary Biotherapeutics Launches With $103 Million
Estuary Biotherapeutics secures $103 million to develop gene therapies for kidney disease.
In brief
Estuary Biotherapeutics secures $103 million to develop gene therapies for kidney disease. Estuary Biotherapeutics received $103 million to create gene therapies targeting kidney disease. Originally reported by Pulse 2.0.
Estuary Biotherapeutics Launches
Estuary Biotherapeutics has launched with $103 million in committed financing to develop genetic medicines targeting serious kidney diseases.
Funding Sources
The financing includes a $93 million Series A led by RA Capital Management with participation from Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund and a…
Lead Programs
The proceeds will support Estuary’s two lead programs, EST-201 and EST-101, through clinical proof of concept and further development of the company’s kidney-targeting platform.
Program Targets
EST-201 targets patients with ADPKD caused by PKD2 mutations, while EST-101 targets patients with PKD1 mutations.
Clinical Timeline
Estuary anticipates bringing EST-201 into the clinic in 2027 and EST-101 into the clinic in 2028.
The takeaway
Estuary Biotherapeutics received $103 million to create gene therapies targeting kidney disease.
